Spero Therapeutics (NASDAQ:SPRO) has been given a $27.00 price objective by equities research analysts at Cantor Fitzgerald in a research note issued to investors on Thursday. The firm presently has a “buy” rating on the stock. Cantor Fitzgerald’s price target indicates a potential upside of 80.36% from the stock’s previous close.
Other equities research analysts have also recently issued research reports about the company. Oppenheimer set a $30.00 target price on Spero Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, April 3rd. Zacks Investment Research raised Spero Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research note on Tuesday, January 30th. Finally, ValuEngine raised Spero Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Friday, February 2nd. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Spero Therapeutics currently has an average rating of “Hold” and an average price target of $24.25.
Spero Therapeutics stock traded down $0.02 during trading on Thursday, reaching $14.97. 1,536 shares of the company were exchanged, compared to its average volume of 31,746. Spero Therapeutics has a 52-week low of $9.66 and a 52-week high of $15.40. The company has a market cap of $212.66 and a price-to-earnings ratio of -0.84.
Hedge funds have recently bought and sold shares of the business. TIAA CREF Investment Management LLC acquired a new stake in Spero Therapeutics during the fourth quarter worth $103,000. California State Teachers Retirement System acquired a new stake in Spero Therapeutics during the fourth quarter worth $112,000. Dean Capital Investments Management LLC acquired a new stake in Spero Therapeutics during the fourth quarter worth $118,000. Deutsche Bank AG acquired a new stake in Spero Therapeutics during the fourth quarter worth $155,000. Finally, California Public Employees Retirement System acquired a new stake in shares of Spero Therapeutics in the fourth quarter valued at $294,000. 46.28% of the stock is owned by institutional investors.
WARNING: This piece was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://dakotafinancialnews.com/2018/04/12/cantor-fitzgerald-analysts-give-spero-therapeutics-spro-a-27-00-price-target.html.
About Spero Therapeutics
Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections in the United States. It is developing SPR994, an oral carbapenem-class antibiotic for use in adults to treat MDR gram-negative infections; SPR741 that has completed Phase I clinical trial to treat MDR gram-negative infections in the hospital setting; SPR206, an agent that is in preclinical development stage to disrupt the outer membrane of gram-negative bacteria; and SPR720, an oral antibiotic that is in preclinical development stage for the treatment of pulmonary non-tuberculous mycobacterial infections.
Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.